GB9625051D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB9625051D0
GB9625051D0 GB9625051A GB9625051A GB9625051D0 GB 9625051 D0 GB9625051 D0 GB 9625051D0 GB 9625051 A GB9625051 A GB 9625051A GB 9625051 A GB9625051 A GB 9625051A GB 9625051 D0 GB9625051 D0 GB 9625051D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9625051A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to GB9625051A priority Critical patent/GB9625051D0/en
Publication of GB9625051D0 publication Critical patent/GB9625051D0/en
Priority to JP10502496A priority patent/JP2000510153A/en
Priority to TR1998/02667T priority patent/TR199802667T2/en
Priority to AU31020/97A priority patent/AU722541B2/en
Priority to US09/202,493 priority patent/US6071927A/en
Priority to SK1753-98A priority patent/SK175398A3/en
Priority to EP97926140A priority patent/EP0906315A1/en
Priority to CZ984247A priority patent/CZ424798A3/en
Priority to YU59098A priority patent/YU59098A/en
Priority to CA002257964A priority patent/CA2257964A1/en
Priority to EA199900045A priority patent/EA001574B1/en
Priority to PCT/GB1997/001630 priority patent/WO1997049710A1/en
Priority to BR9709915A priority patent/BR9709915A/en
Priority to KR1019980710463A priority patent/KR20000022060A/en
Priority to PL97330235A priority patent/PL330235A1/en
Priority to NZ332777A priority patent/NZ332777A/en
Priority to IL12690097A priority patent/IL126900A0/en
Priority to EE9800459A priority patent/EE9800459A/en
Priority to AU55594/98A priority patent/AU734872B2/en
Priority to AT97952023T priority patent/ATE282416T1/en
Priority to EP97952024A priority patent/EP0942732B1/en
Priority to CA002273806A priority patent/CA2273806A1/en
Priority to JP52522398A priority patent/JP2001508412A/en
Priority to EP97952021A priority patent/EP0941093B1/en
Priority to EP97953724A priority patent/EP0942735A1/en
Priority to JP52517198A priority patent/JP2001504849A/en
Priority to CA002273800A priority patent/CA2273800A1/en
Priority to AT97952021T priority patent/ATE288756T1/en
Priority to AT97952052T priority patent/ATE293975T1/en
Priority to EP97952020A priority patent/EP0942729B1/en
Priority to CA002273786A priority patent/CA2273786A1/en
Priority to CA002273807A priority patent/CA2273807A1/en
Priority to DE69733148T priority patent/DE69733148T2/en
Priority to CA002273351A priority patent/CA2273351A1/en
Priority to AT97952020T priority patent/ATE274908T1/en
Priority to ES97952021T priority patent/ES2236838T3/en
Priority to CA002273810A priority patent/CA2273810A1/en
Priority to AU55589/98A priority patent/AU733855B2/en
Priority to PCT/EP1997/006683 priority patent/WO1998024439A1/en
Priority to JP52517298A priority patent/JP2001504850A/en
Priority to CA002273856A priority patent/CA2273856A1/en
Priority to AU55591/98A priority patent/AU736042B2/en
Priority to AT97952019T priority patent/ATE285776T1/en
Priority to EP97952052A priority patent/EP0942733B1/en
Priority to JP52517498A priority patent/JP2001504852A/en
Priority to AU55613/98A priority patent/AU734860B2/en
Priority to PCT/EP1997/006691 priority patent/WO1998024445A1/en
Priority to PCT/EP1997/006684 priority patent/WO1998024440A1/en
Priority to PCT/EP1997/006686 priority patent/WO1998024441A1/en
Priority to DE69730515T priority patent/DE69730515T2/en
Priority to ES97952020T priority patent/ES2227728T3/en
Priority to DE69731658T priority patent/DE69731658T2/en
Priority to ES97952023T priority patent/ES2231901T3/en
Priority to CA002273809A priority patent/CA2273809A1/en
Priority to PCT/EP1997/006688 priority patent/WO1998024443A1/en
Priority to ES97952019T priority patent/ES2234039T3/en
Priority to JP52517698A priority patent/JP2001505881A/en
Priority to EP97953721A priority patent/EP0942734A1/en
Priority to PCT/EP1997/006940 priority patent/WO1998024447A1/en
Priority to PCT/EP1997/006692 priority patent/WO1998024446A1/en
Priority to CA002273853A priority patent/CA2273853A1/en
Priority to AU55590/98A priority patent/AU731676B2/en
Priority to PCT/EP1997/006687 priority patent/WO1998024442A1/en
Priority to EP97952019A priority patent/EP0941092B1/en
Priority to DE69731657T priority patent/DE69731657T2/en
Priority to EP97951270A priority patent/EP0942728A1/en
Priority to DK97952020T priority patent/DK0942729T3/en
Priority to ES97952024T priority patent/ES2231902T3/en
Priority to JP52516998A priority patent/JP2001504847A/en
Priority to EP97952023A priority patent/EP0942731B1/en
Priority to AT97952024T priority patent/ATE282417T1/en
Priority to PCT/EP1997/006690 priority patent/WO1998024444A1/en
Priority to DE69732492T priority patent/DE69732492T2/en
Priority to JP52517598A priority patent/JP2001504853A/en
Priority to AU57527/98A priority patent/AU729708B2/en
Priority to PCT/EP1997/006682 priority patent/WO1998024438A1/en
Priority to AU55593/98A priority patent/AU731674B2/en
Priority to AU54858/98A priority patent/AU731349B2/en
Priority to DE69732133T priority patent/DE69732133T2/en
Priority to JP52517098A priority patent/JP2001504848A/en
Priority to AU55592/98A priority patent/AU731672B2/en
Priority to JP52517798A priority patent/JP2001507678A/en
Priority to CA002273785A priority patent/CA2273785A1/en
Priority to PT97952020T priority patent/PT942729E/en
Priority to JP52517398A priority patent/JP2001504851A/en
Priority to EP97952022A priority patent/EP0942730A1/en
Priority to AU57530/98A priority patent/AU732633B2/en
Priority to TW086117779A priority patent/TW466240B/en
Priority to IDP973779A priority patent/ID19017A/en
Priority to US08/980,730 priority patent/US5929054A/en
Priority to CO97070178A priority patent/CO4910154A1/en
Priority to US08/980,931 priority patent/US5925627A/en
Priority to PE00108297A priority patent/PE20099A1/en
Priority to US08/980,928 priority patent/US6096729A/en
Priority to HRP970648 priority patent/HRP970648A2/en
Priority to US08/982,053 priority patent/US5952315A/en
Priority to US08/980,927 priority patent/US5919781A/en
Priority to US09/096,414 priority patent/US5977104A/en
Priority to US09/095,782 priority patent/US6100256A/en
Priority to US09/096,216 priority patent/US6114315A/en
Priority to US09/096,039 priority patent/US6613765B1/en
Priority to IS4909A priority patent/IS4909A/en
Priority to BG102998A priority patent/BG102998A/en
Priority to NO985977A priority patent/NO985977L/en
Priority to CY0500004A priority patent/CY2499B1/en
Pending legal-status Critical Current

Links

GB9625051A 1996-06-21 1996-12-02 Therapeutic agents Pending GB9625051D0 (en)

Priority Applications (105)

Application Number Priority Date Filing Date Title
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents
JP10502496A JP2000510153A (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutics
TR1998/02667T TR199802667T2 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agent.
AU31020/97A AU722541B2 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
US09/202,493 US6071927A (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
SK1753-98A SK175398A3 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
EP97926140A EP0906315A1 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
CZ984247A CZ424798A3 (en) 1996-06-21 1997-06-17 Spiropiperidine derivatives, process of their preparation and pharmaceutical composition containing thereof
YU59098A YU59098A (en) 1996-06-21 1997-06-17 Substituted spiro-piperidine derivatives
CA002257964A CA2257964A1 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
EA199900045A EA001574B1 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents.
PCT/GB1997/001630 WO1997049710A1 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
BR9709915A BR9709915A (en) 1996-06-21 1997-06-17 Compound pharmaceutical composition use of the compound and processes for the treatment or prevention of physiological disorders associated with an excess of tachykinins and for the preparation of the compound
KR1019980710463A KR20000022060A (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
PL97330235A PL330235A1 (en) 1996-06-21 1997-06-17 Derivatives of spiropiperidine and their application as therapeutic agents
NZ332777A NZ332777A (en) 1996-06-21 1997-06-17 3,6-bi-phenyl substituted spiro-piperidine derivatives
IL12690097A IL126900A0 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
EE9800459A EE9800459A (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents
AU55594/98A AU734872B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating movement disorders
AT97952023T ATE282416T1 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SUBSTANCE USE DISORDERS
EP97952024A EP0942732B1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating movement disorders
CA002273806A CA2273806A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating substance use disorders
JP52522398A JP2001508412A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of cognitive impairment
EP97952021A EP0941093B1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
EP97953724A EP0942735A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating schizophrenic disorders
JP52517198A JP2001504849A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of stress disorders
CA002273800A CA2273800A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
AT97952021T ATE288756T1 (en) 1996-12-02 1997-11-25 USE OF NK-1 RECEPTOR ANTAGONISTS TO TREAT SEVERE DEPRESSION ACCOMPANIED BY ANXIETY
AT97952052T ATE293975T1 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDERS
EP97952020A EP0942729B1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating stress disorders
CA002273786A CA2273786A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating stress disorders
CA002273807A CA2273807A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating schizophrenic disorders
DE69733148T DE69733148T2 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
CA002273351A CA2273351A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating sexual dysfunction
AT97952020T ATE274908T1 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENTS OF STRESS DISORDERS
ES97952021T ES2236838T3 (en) 1996-12-02 1997-11-25 USE OF NK-1 RECEPTOR ANTAPHONISTS FOR THE TREATMENT OF SERIOUS DEPRESSIVE DISORDERS WITH ANXIETY.
CA002273810A CA2273810A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating major depressive disorders
AU55589/98A AU733855B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating major depressive disorders
PCT/EP1997/006683 WO1998024439A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating severe anxiety disorders
JP52517298A JP2001504850A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist to treat severe depressive disorder with anxiety
CA002273856A CA2273856A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating bipolar disorders
AU55591/98A AU736042B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AT97952019T ATE285776T1 (en) 1996-12-02 1997-11-25 METHOD AND DEVICE FOR COMPENSATING LUMINANCE DISTURBANCES CAUSED BY CHROME SIGNAL PROCESSING
EP97952052A EP0942733B1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating cognitive disorders
JP52517498A JP2001504852A (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonist for the treatment of bipolar disorder
AU55613/98A AU734860B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating cognitive disorders
PCT/EP1997/006691 WO1998024445A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating schizophrenic disorders
PCT/EP1997/006684 WO1998024440A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating stress disorders
PCT/EP1997/006686 WO1998024441A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
DE69730515T DE69730515T2 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENTS OF STRESS DISORDERS
ES97952020T ES2227728T3 (en) 1996-12-02 1997-11-25 USE OF NK-1 RECEIVER ANTAGONISTS TO TREAT ESTS DISORDERS.
DE69731658T DE69731658T2 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MOTION FLUCTUATIONS
ES97952023T ES2231901T3 (en) 1996-12-02 1997-11-25 USE OF NK-1 RECEIVER ANTAGONISTS TO TREAT DISORDERS FOR THE USE OF SUBSTANCES.
CA002273809A CA2273809A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating movement disorders
PCT/EP1997/006688 WO1998024443A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating bipolar disorders
ES97952019T ES2234039T3 (en) 1996-12-02 1997-11-25 USE OF NK-1 RECEIVER ANTAGONISTS TO TREAT MORE DEPRESSION DISORDERS.
JP52517698A JP2001505881A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist to treat schizophrenia disease
EP97953721A EP0942734A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating severe anxiety disorders
PCT/EP1997/006940 WO1998024447A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating cognitive disorders
PCT/EP1997/006692 WO1998024446A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating movement disorders
CA002273853A CA2273853A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating cognitive disorders
AU55590/98A AU731676B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating stress disorders
PCT/EP1997/006687 WO1998024442A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating sexual dysfunction
EP97952019A EP0941092B1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating major depressive disorders
DE69731657T DE69731657T2 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SUBSTANCE USE ERRORS
EP97951270A EP0942728A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating sexual dysfunction
DK97952020T DK0942729T3 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for the treatment of stress disorders
ES97952024T ES2231902T3 (en) 1996-12-02 1997-11-25 USE OF NK-1 RECEIVER ANTAGONISTS FOR THE TREATMENT OF MOVEMENT DISORDERS.
JP52516998A JP2001504847A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of major depressive disorder
EP97952023A EP0942731B1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating substance use disorders
AT97952024T ATE282417T1 (en) 1996-12-02 1997-11-25 THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MOVEMENT DISORDERS
PCT/EP1997/006690 WO1998024444A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating substance use disorders
DE69732492T DE69732492T2 (en) 1996-12-02 1997-11-25 USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEAVY DEPRESSIONS ACCOMPANIED BY ANXIETY STATES
JP52517598A JP2001504853A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of a substance use disorder
AU57527/98A AU729708B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating severe anxiety disorders
PCT/EP1997/006682 WO1998024438A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating major depressive disorders
AU55593/98A AU731674B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating substance use disorders
AU54858/98A AU731349B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating sexual dysfunctions
DE69732133T DE69732133T2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for the treatment of major depression
JP52517098A JP2001504848A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of severe anxiety disorder
AU55592/98A AU731672B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating bipolar disorders
JP52517798A JP2001507678A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of movement disorders
CA002273785A CA2273785A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating severe anxiety disorders
PT97952020T PT942729E (en) 1996-12-02 1997-11-25 UTILIZATION OF NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF STRESSE DISEASES
JP52517398A JP2001504851A (en) 1996-12-02 1997-11-25 Use of an NK-1 receptor antagonist for the treatment of sexual dysfunction
EP97952022A EP0942730A1 (en) 1996-12-02 1997-11-25 Use of nk-1 receptor antagonists for treating bipolar disorders
AU57530/98A AU732633B2 (en) 1996-12-02 1997-11-25 Use of NK-1 receptor antagonists for treating schizophrenic disorders
TW086117779A TW466240B (en) 1996-06-21 1997-11-26 Spiro-piperidine derivatives and pharmaceutical composition comprising the same
IDP973779A ID19017A (en) 1996-12-02 1997-11-27 SPIRO-PIPERIDIN DECREASES AND THE USE OF THERAPEUTIC MATERIALS
US08/980,730 US5929054A (en) 1996-12-02 1997-12-01 Use of NK-1 receptor antagonists for treating sexual dysfunctions
CO97070178A CO4910154A1 (en) 1996-12-02 1997-12-01 DERIVATIVES OF SPIRO-PIPERIDINE AND THEIR USE AS TERA-PEUTICAL AGENTS
US08/980,931 US5925627A (en) 1996-12-02 1997-12-01 Use of NK-1 receptor antagonists for treating movement disorders
PE00108297A PE20099A1 (en) 1996-12-02 1997-12-01 DERIVATIVES OF SPIRO-PIPERIDINE AND ITS USE AS THERAPEUTIC AGENTS
US08/980,928 US6096729A (en) 1996-12-02 1997-12-01 Use of NK-1 receptor antagonists for treating amnestic disorders
HRP970648 HRP970648A2 (en) 1996-12-02 1997-12-01 Spiro-piperidine derivatives and their use as therapeutic agents
US08/982,053 US5952315A (en) 1996-12-02 1997-12-01 Use of NK-1 receptor antagonists for treating bipolar disorders
US08/980,927 US5919781A (en) 1996-12-02 1997-12-01 Use of NK-1 receptor antogonists for treating substance use disorders
US09/096,414 US5977104A (en) 1996-12-02 1998-06-11 Use of NK-1 receptor antagonists for treating bipolar disorders
US09/095,782 US6100256A (en) 1996-12-02 1998-06-11 Use of NK-1 receptors antagonists for treating schizophrenic disorders
US09/096,216 US6114315A (en) 1996-12-02 1998-06-11 Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US09/096,039 US6613765B1 (en) 1996-12-02 1998-06-11 Use of NK-1 receptor antagonists for treating major depressive disorders
IS4909A IS4909A (en) 1996-06-21 1998-11-27 Spiro-piperidine derivatives and their use as pharmaceutical agents
BG102998A BG102998A (en) 1996-06-21 1998-12-08 Spiro-piperidine derivatives and their application as therapeutical forms
NO985977A NO985977L (en) 1996-06-21 1998-12-18 Spiro-piperidine derivatives and their use as therapeutic agents
CY0500004A CY2499B1 (en) 1996-12-02 2005-01-10 Use of nk-1 receptor antagonists for treating stress disorders.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB9625051D0 true GB9625051D0 (en) 1997-01-22

Family

ID=10803817

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9625051A Pending GB9625051D0 (en) 1996-06-21 1996-12-02 Therapeutic agents

Country Status (1)

Country Link
GB (1) GB9625051D0 (en)

Similar Documents

Publication Publication Date Title
GB9601724D0 (en) Therapeutic agents
PL338920A1 (en) Therapeutic agents
GB9708484D0 (en) Therapeutic agents
GB9708945D0 (en) Therapeutic agents
GB9704948D0 (en) Therapeutic agents
GB9702524D0 (en) Therapeutic agents
GB9627005D0 (en) Therapeutic agents
GB9711753D0 (en) Therapeutic agents
GB9713707D0 (en) Therapeutic agents
GB9715977D0 (en) Therapeutic agents
GB9711114D0 (en) Therapeutic agents
GB9600235D0 (en) Therapeutic agents
GB9603755D0 (en) Therapeutic agents
GB9613969D0 (en) Therapeutic agents
GB9615449D0 (en) Therapeutic agents
GB9702392D0 (en) Therapeutic agents
GB9605065D0 (en) Therapeutic agents
GB9609374D0 (en) Therapeutic agents
ZA9711551B (en) Therapeutic agents
GB9700555D0 (en) Therapeutic agents
GB9610979D0 (en) Therapeutic agents
GB9604036D0 (en) Therapeutic agents
GB9603136D0 (en) Therapeutic agents
GB9615658D0 (en) Therapeutic agents
GB9601786D0 (en) Therapeutic agents